Skip to main content
Praxis Precision Medicines, Inc. logo

Praxis Precision Medicines, Inc. — Investor Relations & Filings

Ticker · PRAX ISIN · US74006W2070 US Manufacturing
Open in API
Filings indexed 458 across all filing types
Latest filing 2024-05-13 Interim / Quarterly Rep…
Country US United States of America
Listing US PRAX

About Praxis Precision Medicines, Inc.

https://praxismedicines.com/

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company that develops therapies for central nervous system (CNS) disorders. The company's methodology involves translating insights from genetic epilepsies into treatments for conditions characterized by neuronal excitation-inhibition imbalance. Praxis employs a genetics-focused approach, utilizing translational tools and patient-guided development strategies to advance its portfolio. The developmental pipeline includes several clinical-stage assets and numerous early-stage programs designed to address complex brain disorders.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2024
2024-05-13 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 13, 2024, by Praxis Precision Medicines, Inc. It announces the company's financial results for the quarter ended March 31, 2024, and includes a press release as an exhibit. The document is a current report providing updates on recent financial results and cash position but does not contain the full quarterly financial statements or detailed financial analysis itself. The presence of a press release and the nature of the content indicate this is an initial announcement of quarterly financial results rather than a comprehensive interim report. Therefore, the document fits the definition of an Earnings Release (ER).
2024-05-13 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is identified as a Schedule 14A filing, which is a Proxy Statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is labeled as "Definitive Additional Materials" related to the proxy statement. Proxy statements are materials sent to shareholders to provide information and request votes for meetings. The document is short (1094 characters) and does not contain financial statements or detailed financial data, but rather proxy solicitation materials. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI).
2024-04-26 English
DEF 14A
Proxy Solicitation & Information Statement
2024-04-26 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It details an underwriting agreement for a stock offering, including the issuance of common stock and pre-funded warrants, the pricing, the expected proceeds, and the intended use of the funds. It also references exhibits such as the underwriting agreement and legal opinion. The document is not a full financial report but an announcement of a capital raising event. Therefore, it fits the category of Capital/Financing Update (CAP). The document length (11,357 characters) is sufficient to contain substantive information about the financing event, not just a brief announcement or a certification. Hence, the classification is CAP with high confidence.
2024-03-29 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of common stock and pre-funded warrants by Praxis Precision Medicines, Inc. It includes detailed offering terms, underwriting information, risk factors, and legal disclaimers. The document is a registration and offering prospectus supplement, which is a type of capital raising disclosure. It is not a financial report, earnings release, management discussion, or any other type of report. It is clearly an update on financing activity and capital structure changes related to a stock offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a regulatory filing fallback, but a full prospectus supplement.
2024-03-29 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.